medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2012, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2012; 10 (1)

Vogt-Koyanagi-Harada Syndrome

Caviedes MP, Baztan PMC, Guzzi MM, Staiger H, Torre AC, Volonteri VI, Galimberti RL

Language: Spanish
References: 23
Page: 33-36
PDF size: 156.33 Kb.


ABSTRACT

Vogt-Koyanagi-Harada disease is an infrequent, systemic syndrome that evolves in stages and compromises organs containing melanocytes. Typically, patients experience four different phases: meningoencephalitic, uveitic, convalescence with dermatologic involvement, and the chronic phase. Treatment of choice is high dose corticosteroids which may be combined with immunosuppressive agents. It should be initiated as early as possible to prevent eye damage.
We present the case of a patient with the first two phases of the disease in addition to erythema multiform lesions. During convalescence phase, and in coincidence with the location of the latter, he developed vitiligo lesions that complete the syndrome.


REFERENCES

  1. Heller M, Guinle L, Airaudo M, Massone C, et al. “Síndrome de Vogt- Koyanagi-Harada”. Dermatol Arg 2007; 13: 120-124.

  2. Barnes L. “Vitiligo and the Vogt-Koyanagi-Harada syndrome”. Dermatol Clin 1988; 6: 229-239.

  3. Okada T, Sakamoto T, Ishibashi T, Inomata H. “Vitiligo in Vogt-Koyanagi- Harada disease: immunohistological analysis of inflammatory site”. Graefes Arch Clin Exp Ophthalmol 1996; 234: 359-363.

  4. Srivastava VK, Khan AS. “Vogt Koyanagi Harada syndrome”. Indian J Dermatol Venereol Leprol 1992; 58: 340-342.

  5. Park S, Albert DM, Bolognia JL. “Ocular manifestations of pigmentary disorders”. Dermatol Clin 1992; 10: 609-622.

  6. Goldberg AC, Yamamoto JM, Chiarella JM, et al. “HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease”. Hum Inmunol 1998; 59: 183-188.

  7. Da Silva G, Damico FM, Marin ML, Golgberg AC, et al. “Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: considerations on the different disease categories”. Am J Ophthalmol 2009; 147: 339-345.

  8. Tsuruta D, Hamada T, Teramae H, Mito H, et al. “Inflammatory vitiligo in Vogt-Koyanagi-Harada disease”. J Am Acad Dermatol 2001; 44: 129-131.

  9. Damico FM, Bezerra FT, Carvalho da Silva G, Gasparin F, et al. “New insights into Vogt-Koyanagi-Harada disease”. Arq Bras Oftalmol 2009; 72: 413-420.

  10. Chi W, Yang P, Li B, Wu C, et al. “IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease”. J Allergy Clin Immunol 2007; 119: 1218-1224.

  11. Huggins RH, Janusz CA, Schwartz RA. “Vitiligo: A sign of systemic disease”. Indian J Dermatol Venereol Leprol 2006; 72: 68-71.

  12. De Domingo B, Blanco MJ, Rodríguez Cid MJ, Piñeiro A, et al. “Síndrome de Vogt Koyanagi Harada”. Arch Soc Esp Oftalmol 2008; 83: 385-390.

  13. Horie Y, Kitaichi N, Takemoto Y, Namba K, et al. “Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease”. Mol Vis 2007; 13: 2334-2338.

  14. Hercogová J, Buggiani G, Prignano F, Lotti T. “A rational approach to the treatment of vitiligo and other hypomelanoses”. Dermatol Clin 2007; 25: 383-392.

  15. González Delgado M, et al. “Inmunoglobulinas en el Síndrome de Vogt- Koyanagi-Harada”. Neurología 2004; 19: 401-403.

  16. Wong SS, Ng SK, Lee HM. “Vogt-Koyanagi-Harada disease: extensive vitiligo with prodromal generalized erythroderma”. Dermatology 1999; 198: 65-68.

  17. Cabrera HN, Dahbar MA, Allevato MA. “Síndrome de Vogt-Koyanagi- Harada. Iniciación con nevo de Sutton”. Rev Bol de Dermatol 2003; 2: 22-25.

  18. Haque WM, Mir MR, Hsu S. “Vogt-Koyanagi-Harada syndrome: Association with alopecia areata”. Dermatol Online J 2009; 15: 10.

  19. Tanioka M, Yamamoto Y, Katoh M, Takahashi K, et al. “Vitiligo vulgaris and autoimmune diseases in Japan: A report from vitiligo clinic in Kyoto University Hospital”. Dermatoendocrinol 2009; 1: 43-45.

  20. Jaggarao N, Voth D, Jacobsen J. “The Vogt-Koyanagi-Harada syndrome: association with hypothyroidism and diabetes mellitus”. Postgrad Med J 1989; 65: 587-588.

  21. Chuah S, Lynel A, Dronfield M. “Vogt-Koyanagi-Harada syndrome, a rare association of Hodgkin’s disease”. Postgrad Med J 1991; 67: 476-478.

  22. Jovic NS, Nesovic M, Vranjesevic DN, Ciric J, et al. “The Vogt-Koyanagi- Harada syndrome: association with autoimmune polyglandular syndrome type 1”. Postgrad Med J 1996; 72: 495-497.

  23. Lim JH, Lee YN, Kim YS, Kim SG, et al. “Vogt-Koyanagi-Harada disease occurring during pegylated interferon-a2b and ribavirin combination therapy for chronic hepatitis C”. Korean J Hepatol 2011; 17: 61-65.




2020     |     www.medigraphic.com